Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TARA M GRAFF

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1356584080
CMS profile
1308501
Location
CLIVE, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$165,303.05

127 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Kite Pharma, Inc. $31,327.01 10
BeiGene USA, Inc. $25,699.00 26
Genentech USA, Inc. $24,093.42 17
Genmab U.S., Inc. $19,239.49 23
ABBVIE INC. $17,549.31 17
Lilly USA, LLC $16,562.50 6
MorphoSys, US Inc. $9,760.56 4
AstraZeneca Pharmaceuticals LP $8,882.21 8
Adaptive Biotechnologies Corporation $6,456.18 10
ADC Therapeutics America, Inc. $3,199.58 4
Kyowa Kirin, Inc. $2,400.00 1
Eli Lilly and Company $133.79 1

Page 2 of 3; records 51–100 of 127 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TARA M GRAFF

NPI 1356584080 · CMS profile ID 1308501

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

CLIVE, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 127 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356584080?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TARA M GRAFF, NPI 1356584080, CMS profile ID 1308501. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 127 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356584080?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). TARA M GRAFF, NPI 1356584080, CMS profile ID 1308501. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 127 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356584080?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
TARA M GRAFF, NPI 1356584080, CMS profile ID 1308501, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 127 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1356584080?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

127 matching records · $165,303.05 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 127 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 127.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ADC Therapeutics America, Inc. $3,000.0009/29/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053794767 CMS
Lilly USA, LLC $3,125.0009/28/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032245355 CMS
ADC Therapeutics America, Inc. $125.0009/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053794745 CMS
Genentech USA, Inc. $2,530.0009/19/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040575897 CMS
BeiGene USA, Inc. $48.0009/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051193751 CMS
BeiGene USA, Inc. $5,200.0009/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051193753 CMS
BeiGene USA, Inc. $499.8009/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051193755 CMS
Genmab U.S., Inc. $174.2309/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051348753 CMS
Genmab U.S., Inc. $465.2809/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051348771 CMS
Kyowa Kirin, Inc. $2,400.0009/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027026623 CMS
ABBVIE INC. $2,500.0009/07/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997377025 CMS
BeiGene USA, Inc. $39.5709/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051193799 CMS
Genentech USA, Inc. $4,040.0009/07/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040575863 CMS
Genentech USA, Inc. $205.9209/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040575873 CMS
Genentech USA, Inc. $880.1009/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040575879 CMS
Genentech USA, Inc. $66.2009/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040575889 CMS
Genmab U.S., Inc. $3,200.0009/07/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051348755 CMS
Genmab U.S., Inc. $87.6009/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051348759 CMS
Genmab U.S., Inc. $7.0809/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051348761 CMS
Genmab U.S., Inc. $34.9208/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051348757 CMS
Kite Pharma, Inc. $790.0008/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025269429 CMS
AstraZeneca Pharmaceuticals LP $100.0008/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014176805 CMS
ABBVIE INC. $1,750.0008/11/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997377023 CMS
Genmab U.S., Inc. $124.9408/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051348749 CMS
Genentech USA, Inc. $1,520.0007/20/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040575913 CMS
Adaptive Biotechnologies Corporation $1,400.0007/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022972381 CMS
Genentech USA, Inc. $2,020.0006/29/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040575799 CMS
Lilly USA, LLC $1,875.0006/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032229669 CMS
Genentech USA, Inc. $4,040.0006/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040575907 CMS
Genentech USA, Inc. $73.1706/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040575923 CMS
Genentech USA, Inc. $244.9706/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040575928 CMS
Kite Pharma, Inc. $2,765.0006/16/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025269427 CMS
ABBVIE INC. $948.0006/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997377021 CMS
Genmab U.S., Inc. $109.1106/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051348743 CMS
MorphoSys, US Inc. $4.6806/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060325201 CMS
ABBVIE INC. $52.4506/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997377019 CMS
MorphoSys, US Inc. $2,460.0006/08/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060325203 CMS
Kite Pharma, Inc. $1,975.0006/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025269425 CMS
Lilly USA, LLC $3,437.5005/17/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032364227 CMS
BeiGene USA, Inc. $3,900.0005/16/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051193793 CMS
BeiGene USA, Inc. $125.0005/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051193795 CMS
Adaptive Biotechnologies Corporation $350.0005/10/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022972163 CMS
Adaptive Biotechnologies Corporation $700.0005/10/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022972167 CMS
Genentech USA, Inc. $3.0605/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040575841 CMS
Kite Pharma, Inc. $6,720.0005/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025269423 CMS
Kite Pharma, Inc. $348.4605/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025269435 CMS
Genmab U.S., Inc. $35.4804/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051348747 CMS
Genmab U.S., Inc. $124.6004/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051348745 CMS
BeiGene USA, Inc. $19.0004/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051193791 CMS
Genentech USA, Inc. $1,260.0004/11/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040575847 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $40,148.21 54
PY2020 $64,727.61 34
PY2021 $39,925.97 39
PY2022 $69,562.89 60
PY2023 $165,303.05 127
PY2024 $183,781.77 139
PY2025 $138,235.54 142

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $18.82 1
PY2025 Principal investigator $1,210,323.77 88
PY2024 Recipient $6,362.90 2
PY2024 Principal investigator $1,298,881.69 87
PY2023 Recipient $1,199.70 1
PY2023 Principal investigator $75,790.90 11
PY2022 Principal investigator $71,092.92 12
PY2021 Principal investigator $99,041.67 19
PY2020 Principal investigator $19,967.50 2
PY2019 Principal investigator $1,762.50 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

89 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $144.00 12/31/2025 Non-covered Recipient Entity
MISSION CANCER AND BLOOD
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting No dispute reported 06/30/2026 1202533029
Principal investigator 1 Merck Sharp & Dohme LLC $54,684.06 12/31/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma rrcHL or Relapsed or Refractory Primar No dispute reported 06/30/2026 1232928469
Principal investigator 1 Merck Sharp & Dohme LLC $54,684.06 12/31/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma rrcHL or Relapsed or Refractory Primar No dispute reported 06/30/2026 1232928682
Principal investigator 1 Janssen Research & Development, LLC $23,719.50 12/22/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide No dispute reported 06/30/2026 1175428499
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 12/22/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy. No dispute reported 06/30/2026 1175428687
Principal investigator 1 AstraZeneca UK Limited $8,000.00 12/19/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL (ACRUE) No dispute reported 06/30/2026 1185544402
Principal investigator 1 ABBVIE INC. $650.00 12/18/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202428553
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,446.00 12/17/2025 Non-covered Recipient Entity
Exigent Research Llc
A study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1235997423
Principal investigator 1 Incyte Corporation $396.00 12/12/2025 Non-covered Recipient Entity
MISSION CANCER BLOOD JOHN STODDARD CANCER CENTER
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND) No dispute reported 06/30/2026 1240557953
Principal investigator 1 ABBVIE INC. $17,150.40 12/04/2025 Non-covered Recipient Entity
MISSION CANCER + BLOOD
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202528598
Principal investigator 1 ABBVIE INC. $1,300.00 12/01/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202428512
Principal investigator 1 Genentech, Inc. $3,700.00 12/01/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy No dispute reported 06/30/2026 1211561568
Principal investigator 1 Genentech, Inc. $41,255.00 12/01/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy No dispute reported 06/30/2026 1211561572
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 11/10/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide No dispute reported 06/30/2026 1175428187
Principal investigator 1 Janssen Research & Development, LLC $49,373.55 11/07/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide No dispute reported 06/30/2026 1175428467
Principal investigator 1 ABBVIE INC. $1,540.50 11/05/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202428503
Principal investigator 1 ABBVIE INC. $12,359.25 11/04/2025 Non-covered Recipient Entity
MISSION CANCER + BLOOD
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202520599
Principal investigator 1 Janssen Research & Development, LLC $700.00 10/27/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide No dispute reported 06/30/2026 1175428338
Principal investigator 1 Incyte Corporation $100.00 10/22/2025 Non-covered Recipient Entity
MISSION CANCER BLOOD JOHN STODDARD CANCER CENTER
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND) No dispute reported 06/30/2026 1240557959
Principal investigator 1 ABBVIE INC. $357.50 10/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202428501
Principal investigator 1 ABBVIE INC. $2,405.00 09/11/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202428422
Principal investigator 1 BeOne Medicines Ltd. $33,536.00 09/08/2025 Non-covered Recipient Entity
MISSION CANCER AND BLOOD
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190344266
Principal investigator 1 ABBVIE INC. $19,098.45 09/03/2025 Non-covered Recipient Entity
MISSION CANCER + BLOOD
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202508108
Principal investigator 1 Merck Sharp & Dohme LLC $29,943.60 08/31/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma rrcHL or Relapsed or Refractory Primar No dispute reported 06/30/2026 1232928471
Principal investigator 1 Merck Sharp & Dohme LLC $29,943.60 08/31/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma rrcHL or Relapsed or Refractory Primar No dispute reported 06/30/2026 1232928684
Principal investigator 1 Janssen Research & Development, LLC $70,974.35 08/21/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175428208
Principal investigator 1 Eli Lilly and Company $6,123.00 08/20/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) No dispute reported 06/30/2026 1187882038
Principal investigator 1 BeOne Medicines Ltd. $15,720.00 08/18/2025 Non-covered Recipient Entity
MISSION CANCER AND BLOOD
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190342221
Principal investigator 1 Janssen Research & Development, LLC $1,686.00 08/18/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175428377
Principal investigator 1 Eli Lilly and Company $15,400.00 08/12/2025 Non-covered Recipient Entity
MISSION CANCER AND BLOOD PLLC
A PHASE 2, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF 3 DOSES OF PIRTOBRUTINIB IN PARTICIPANTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WHO PREVIOUSLY RECEIVED TREATMENT WITH A COVALENT BRUTON TYROSINE KINASE INHIBITOR No dispute reported 06/30/2026 1187885018
Principal investigator 1 Genentech, Inc. $95,172.00 08/11/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy No dispute reported 06/30/2026 1211561563
Principal investigator 1 Janssen Research & Development, LLC $550.00 08/08/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175428653
Principal investigator 1 ABBVIE INC. $6,228.90 08/06/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202428353
Principal investigator 1 ABBVIE INC. $2,925.00 08/06/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202428357
Principal investigator 1 ABBVIE INC. $7,913.70 08/06/2025 Non-covered Recipient Entity
MISSION CANCER + BLOOD
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202502302
Principal investigator 1 ABBVIE INC. $2,692.30 07/02/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202428284
Principal investigator 1 ABBVIE INC. $10,770.30 07/02/2025 Non-covered Recipient Entity
MISSION CANCER + BLOOD
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202495091
Principal investigator 1 Incyte Corporation $124.50 07/02/2025 Non-covered Recipient Entity
MISSION CANCER BLOOD JOHN STODDARD CANCER CENTER
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND) No dispute reported 06/30/2026 1240557947
Recipient ABBVIE INC. $18.82 06/16/2025 Covered Recipient Physician Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE2122FL-2) No dispute reported 06/30/2026 1202398596
Principal investigator 1 BeOne Medicines Ltd. $31,440.00 06/11/2025 Non-covered Recipient Entity
MISSION CANCER AND BLOOD
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330383
Principal investigator 1 BeOne Medicines Ltd. $31,440.00 06/10/2025 Non-covered Recipient Entity
MISSION CANCER AND BLOOD
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190337050
Principal investigator 1 ABBVIE INC. $43,079.85 06/03/2025 Non-covered Recipient Entity
MISSION CANCER + BLOOD
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202487369
Principal investigator 1 Janssen Research & Development, LLC $10,227.60 06/02/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175428568
Principal investigator 1 BeOne Medicines Ltd. $15,720.00 05/28/2025 Non-covered Recipient Entity
MISSION CANCER AND BLOOD
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336762
Principal investigator 1 Genentech, Inc. $1,000.00 05/19/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211604705
Principal investigator 1 Janssen Research & Development, LLC $3,650.00 05/19/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or No dispute reported 06/30/2026 1175428637
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 05/15/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or No dispute reported 06/30/2026 1175428228
Principal investigator 1 Janssen Research & Development, LLC $350.00 05/08/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or No dispute reported 06/30/2026 1175428182
Principal investigator 1 ABBVIE INC. $5,384.60 05/07/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202428112
Principal investigator 1 ABBVIE INC. $4,496.85 05/07/2025 Non-covered Recipient Entity
MISSION CANCER AND BLOOD
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202482747
Principal investigator 1 ABBVIE INC. $16,852.05 05/07/2025 Non-covered Recipient Entity
MISSION CANCER + BLOOD
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202482819
Principal investigator 1 Janssen Research & Development, LLC $7,249.50 05/01/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175428723
Principal investigator 1 Genentech, Inc. $1,250.00 04/28/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211604698
Principal investigator 1 Genentech, Inc. $1,500.00 04/28/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211604700
Principal investigator 1 Genentech, Inc. $2,000.00 04/28/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211604709
Principal investigator 1 Genentech, Inc. $3,000.00 04/28/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211604722
Principal investigator 1 Genentech, Inc. $1,000.00 04/28/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211604726
Principal investigator 1 Genentech, Inc. $2,000.00 04/28/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211604733
Principal investigator 1 Janssen Research & Development, LLC $4,605.72 04/24/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175428270
Principal investigator 1 Janssen Research & Development, LLC $550.00 04/21/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175428699
Principal investigator 1 BeiGene, Ltd. $31,440.00 04/16/2025 Non-covered Recipient Entity
MISSION CANCER AND BLOOD
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323594
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 04/07/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Borte No dispute reported 06/30/2026 1175428552
Principal investigator 1 ABBVIE INC. $5,384.60 04/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202427979
Principal investigator 1 ABBVIE INC. $12,653.55 04/03/2025 Non-covered Recipient Entity
MISSION CANCER + BLOOD
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202468880
Principal investigator 1 ABBVIE INC. $3,142.00 04/03/2025 Non-covered Recipient Entity
MISSION CANCER PLUS BLOOD PLLC
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202474271
Principal investigator 1 Genentech, Inc. $1,800.00 03/24/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211604678
Principal investigator 1 BeiGene, Ltd. $62,880.00 03/20/2025 Non-covered Recipient Entity
MISSION CANCER AND BLOOD
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190323844
Principal investigator 1 ABBVIE INC. $21,022.20 03/11/2025 Non-covered Recipient Entity
MISSION CANCER + BLOOD
M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202462533
Principal investigator 1 Eli Lilly and Company $476.35 03/10/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
A PHASE 2, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF 3 DOSES OF PIRTOBRUTINIB IN PARTICIPANTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WHO PREVIOUSLY RECEIVED TREATMENT WITH A COVALENT BRUTON TYROSINE KINASE INHIBITOR No dispute reported 06/30/2026 1187888214
Principal investigator 1 ABBVIE INC. $2,510.30 03/07/2025 Non-covered Recipient Entity
MISSION CANCER PLUS BLOOD PLLC
M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202461565
Principal investigator 1 ABBVIE INC. $10,951.20 03/07/2025 Non-covered Recipient Entity
MISSION CANCER PLUS BLOOD PLLC
M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202461573
Principal investigator 1 Janssen Research & Development, LLC $20,000.00 03/07/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or No dispute reported 06/30/2026 1175428612
Principal investigator 1 ABBVIE INC. $2,500.00 03/06/2025 Non-covered Recipient Entity
DES MOINES ONCOLOGY RESEARCH ASSOCIATION
M20-356 - Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202458367
Principal investigator 1 Janssen Research & Development, LLC $10,000.00 03/06/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or No dispute reported 06/30/2026 1175428400
Principal investigator 1 Janssen Research & Development, LLC $22,000.00 03/06/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or No dispute reported 06/30/2026 1175428591
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 02/24/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175428434
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 02/24/2025 Non-covered Recipient Entity
EXIGENT RESEARCH LLC
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175428544
Principal investigator 1 BeiGene, Ltd. $31,440.00 02/19/2025 Non-covered Recipient Entity
MISSION CANCER AND BLOOD
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321932
Principal investigator 1 ABBVIE INC. $455.00 02/13/2025 Non-covered Recipient Entity
MISSION CANCER PLUS BLOOD PLLC
M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202451315
Principal investigator 1 BeiGene, Ltd. $31,440.00 02/12/2025 Non-covered Recipient Entity
MISSION CANCER AND BLOOD
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190325446
Principal investigator 1 ABBVIE INC. $2,510.30 02/06/2025 Non-covered Recipient Entity
MISSION CANCER PLUS BLOOD PLLC
M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202448407
Principal investigator 1 ABBVIE INC. $10,222.20 02/06/2025 Non-covered Recipient Entity
MISSION CANCER + BLOOD
M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202448575
Principal investigator 1 ABBVIE INC. $40,195.60 02/06/2025 Non-covered Recipient Entity
MISSION CANCER PLUS BLOOD PLLC
M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202448579
Principal investigator 1 ABBVIE INC. $1,300.00 01/21/2025 Non-covered Recipient Entity
MISSION CANCER PLUS BLOOD PLLC
M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202440405
Principal investigator 1 BeiGene, Ltd. $31,440.00 01/20/2025 Non-covered Recipient Entity
MISSION CANCER AND BLOOD
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190323810
Principal investigator 1 ABBVIE INC. $5,427.00 01/15/2025 Non-covered Recipient Entity
MISSION CANCER + BLOOD
M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202438717
Principal investigator 1 ABBVIE INC. $96.00 01/07/2025 Non-covered Recipient Entity
MISSION CANCER PLUS BLOOD PLLC
M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202436988
Principal investigator 1 Celgene Corporation $20,964.48 01/03/2025 Non-covered Recipient Entity
Exigent Research Llc
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) No dispute reported 06/30/2026 1222307039
Principal investigator 1 ABBVIE INC. $2,510.30 01/02/2025 Non-covered Recipient Entity
MISSION CANCER PLUS BLOOD PLLC
M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202434887